A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with... von Kothari, R., Doshi, M., Chaithanya, P.K., Thungappa, S.C., Kumar, A., Mallavarapu, K.M., Nagarkar, R., Mahobia, V., Bhatt, N., Priyadarshini, K.L., Gogia, A., Maksud, T., Prasad, S., Kandappan, V., Krishnappa, R.L., Shanthemarahalli Shivanna, P., Talreja, V., Shrivastava, R., Parmar, D.

Volltext